Welcome to Jianke online pharmacy! Sign in Free registration
reminder:The pictures are the real photos of the original products taken by Jianke for reference only; In case of new packaging listing, there may be update lag, please take the physical object as the standard!
Baidu certification

Tigrelol tablets (Belinda)

This product is used in patients with acute coronary syndrome (unstable angina pectoris, non ST segment elevation myocardial infarction or ST segment elevation myocardial infarction), including patients receiving drug treatment and percutaneous coronary intervention (PCI), to reduce the incidence of thrombotic cardiovascular events (see the instructions for details). More role
App download minus 10 yuan
Common name:
Tegrilol tablets
Product No.:
A14202220786
Approval No.:
Gyzz j20171077 (former gyzz j20130020) (inquired by the State Drug Administration)
Jianke price:
¥198.91
Product specification:
90mg * 14 tablets 90mg*168s 90mg*56s
Manufacturer:
AstraZeneca AB
number        Quantity:
Add to list
Tips:
This product is a prescription drug. Please buy it with the prescription paper; it will be delivered by the offline drugstore of Jianke
 
(for assistance, please call400-086-5111
Jianke promises:
Genuine guarantee
Bank remittance / transfer online payment
  • Product introduction
  • instructions
  • Qualification certificate
  • Relevant information
Product name Tigrelol tablets (Belinda)
Main raw materials The active ingredient of this product is tegranolol.
Main role This product is used in patients with acute coronary syndrome (unstable angina pectoris, non ST segment elevation myocardial infarction or ST segment elevation myocardial infarction), including patients receiving drug treatment and percutaneous coronary intervention (PCI), to reduce the incidence of thrombotic cardiovascular events (see the instructions for details).
Product specification 90mg * 14 tablets
Usage and dosage Oral. This product can be taken before or after meals. The initial dose of this product is 180mg (90mg) per load × 2 tablets), and then 1 tablet (90 mg) twice a day. Unless there is a definite contraindication, this product should be used in combination with aspirin. After taking the first dose of loaded aspirin, the maintenance dose of aspirin is 75 ~ 100mg once a day. ACS patients who have received an overloaded dose of clopidogrel can start using tegrilol. If the patient misses a dose, he should take a 90mg tablet (the next dose of the patient) at the scheduled time of the next medication. The treatment time of this product can be up to 12 months, unless there is a clinical indication to discontinue the treatment of this product (see [pharmacology and toxicology]). The medication experience of more than 12 months is still limited. Premature discontinuation of any antiplatelet drugs (including this product) in patients with acute coronary syndrome may increase the risk of cardiovascular death or myocardial infarction caused by underlying diseases. Therefore, premature discontinuation of treatment should be avoided.
manufacturing enterprise AstraZeneca AB
Jianke commitment
  • Genuine guarantee, formal invoice

    Jianke.com is an approved (B2C) Internet drug legitimate business enterprise in Guangdong Province. It signs a direct supply agreement with the manufacturer and can issue formal invoices for the purchased goods.

  • Private packaging, privacy protection

    When jianke.com packages and delivers goods, the appearance of the packing box only displays the necessary information for delivery, and the name of the purchased goods will not appear. The specific shopping list is in the package to protect the privacy of customers.

  • Efficient logistics and safe arrival

    All products of jianke.com adopt the door-to-door distribution mode of third-party logistics. They are delivered to the nearest warehouse according to your distribution address, so as to deliver them to you on time.

  • Three warehouses to ensure inventory

    Jianke.com has three warehouses in Guangzhou, Dongguan and Wuhan, equipped with first-class equipment, constant temperature and humidity to ensure drug quality. Special personnel are assigned to manage and ensure product inventory.

[drug name] Tigrelol tablets (Belinda)

[common name] Tegrilol tablets

[specification and model] 90mg * 14 tablets

[manufacturer] AstraZeneca AB

[drug type] Western medicine

[approval No.] Gyzz j20171077 (former gyzz j20130020)

[validity period] 24 months

[functional indications] This product is used in patients with acute coronary syndrome (unstable angina pectoris, non ST segment elevation myocardial infarction or ST segment elevation myocardial infarction), including patients receiving drug treatment and percutaneous coronary intervention (PCI), to reduce the incidence of thrombotic cardiovascular events (see the instructions for details).

[usage and dosage] Oral. This product can be taken before or after meals. The initial dose of this product is 180mg (90mg) per load × 2 tablets), and then 1 tablet (90 mg) twice a day. Unless there is a definite contraindication, this product should be used in combination with aspirin. After taking the first dose of loaded aspirin, the maintenance dose of aspirin is 75 ~ 100mg once a day. ACS patients who have received an overloaded dose of clopidogrel can start using tegrilol. If the patient misses a dose, he should take a 90mg tablet (the next dose of the patient) at the scheduled time of the next medication. The treatment time of this product can be up to 12 months, unless there is a clinical indication to discontinue the treatment of this product (see [pharmacology and toxicology]). The medication experience of more than 12 months is still limited. Premature discontinuation of any antiplatelet drugs (including this product) in patients with acute coronary syndrome may increase the risk of cardiovascular death or myocardial infarction caused by underlying diseases. Therefore, premature discontinuation of treatment should be avoided.

[adverse reactions] 1. Hyperuricemia, elevated serum uric acid. 2. Cerebral hemorrhage, intracranial hemorrhage, hemorrhagic stroke. 3. Dyspnea, exertional dyspnea, dyspnea at rest and dyspnea at night. 4. Gastrointestinal bleeding, rectal bleeding, small intestinal bleeding, black stool and occult blood. 5. Gastrointestinal ulcer bleeding, gastric ulcer bleeding, duodenal ulcer bleeding and peptic ulcer bleeding. 6. Subcutaneous hematoma, skin bleeding, subcutaneous bleeding and ecchymosis. 7. Contusion, hematoma, ecchymosis, contusion increasing tendency and traumatic hematoma. 8. Hematuria, blood in urine and urethral bleeding. 9. Blood vessel puncture site bleeding, blood vessel puncture site hematoma, injection site bleeding, puncture site bleeding and catheter site bleeding.

[precautions] 1. Patients with bleeding tendency (such as recent trauma, recent surgery, coagulation dysfunction, activity or recent gastrointestinal bleeding) should use this product with caution. This product is forbidden for patients with active pathological bleeding, patients with a history of intracranial hemorrhage and patients with moderate to severe liver damage. 2. For patients undergoing elective surgery, if antiplatelet drug treatment is not necessary, tigrelol should be stopped 7 days before operation. 3. Discontinuation of tigrelol tablets should be avoided. If tegrilol must be temporarily discontinued (e.g. for bleeding or elective surgery), treatment should be restarted as soon as possible. Discontinuation of tigrelol increases the risk of myocardial infarction, stent thrombosis and death. 4. For caution, tigrelol is not recommended for patients with urinary acid nephropathy. 5. The combination of tigrelol and CYP3A4 strong inhibitors (such as ketoconazole, clarithromycin, naftazone, ritonavir and azanavir) should be avoided, because the combination may significantly increase the exposure of tigrelol (see [drug interaction]). 6. The combination of tigrelol and CYP3A4 strong inducers (such as rifampicin, dexamethasone, phenytoin, carbamazepine and phenobarbital) is not recommended, because the combination may reduce the exposure and effectiveness of tigrelol. 7. Tigritol is not recommended in combination with CYP3A4 substrates with narrow therapeutic index (i.e. cisapride and ergot alkaloids), because tigritol may increase the exposure of these drugs. 8. It is not recommended to use tegrilol in combination with simvastatin greater than 40mg or lovastatin. 9. Dizziness and confusion are reported during the treatment of acute coronary syndrome. Therefore, patients with these symptoms should be extra careful when driving or operating machinery. Please read the instructions carefully and follow the doctor's advice.

[taboo] 1. People who are allergic to tigrelol or any excipients of this product. 2. Patients with active pathological bleeding (such as peptic ulcer or intracranial hemorrhage). 3. Those with a history of intracranial hemorrhage. 4. Patients with moderate to severe liver damage. 5. Because the combined use of tigrelol can significantly increase the exposure of tigrelol, it is prohibited to use tigrelol tablets in combination with powerful CYP3A4 inhibitors (such as ketoconazole, clarithromycin, nefazodone, ritonavir and azanavir).

[listing Permit Holder] AstraZenecaAB

[packaging unit] box

[main ingredients] The active ingredient of this product is tegranolol.

[character] This product is a yellow film coated tablet, which turns white or off white after removing the coating.

[applicable population] unlimited

[medication for pregnant and lactating women] 1. Pregnancy There are no controlled studies on the use of tegrilol in pregnant women. Animal studies have shown that tegranolol can cause fetal malformation when the mother receives about 5 ~ 7 times the maximum recommended dose (mrhd, according to body surface area). Tigrelol should only be used during pregnancy if the potential benefits outweigh the risks to the fetus. 2. Breastfeeding Whether tegrilol or its active metabolites will be secreted into human milk is still unknown. Tegranolol can be secreted through rat milk. Since many drugs can be secreted into human milk and tegranolol may have potentially serious adverse reactions to lactating infants, it should be decided whether to stop lactation or discontinue drugs after considering the importance of tegranolol to mothers.

[medication for children] The safety and efficacy of this product in children under the age of 18 have not been determined.

[medication for elderly patients] There is no need to adjust the dose. In the Plato study, 43% of patients were ≥ 65 years old and 15% were ≥ 75 years old. The relative bleeding risk was similar in each treatment group and age group. There was no difference in safety or efficacy between elderly patients and young patients. However, according to clinical experience, it can not be determined that the pharmacodynamic differences between elderly and young patients are consistent, and some elderly patients are more sensitive to drugs can not be ruled out.

[storage] Store below 30 ℃.

Praise degree

zero%

    reminder

    Dear customer:

    In case of emergency, please call the ordering hotline400-086-5111Consult a health care professional pharmacist.

    Tigrelol tablets (Belinda)

    ¥198.91

    reminder

    To ensure your privacy, please enter the verification code and click "confirm callback". Our customer service staff will call back the phone number you entered later!

    Please enter the correct verification code!
    Loding...
    Can't see clearly. Change one

    Dear customer:

    Your callback failed this time. Please re-enter the verification code to try. Thank you!